KR20170023417A - Methods for producing L-carnosine zinc complex - Google Patents

Methods for producing L-carnosine zinc complex Download PDF

Info

Publication number
KR20170023417A
KR20170023417A KR1020150114980A KR20150114980A KR20170023417A KR 20170023417 A KR20170023417 A KR 20170023417A KR 1020150114980 A KR1020150114980 A KR 1020150114980A KR 20150114980 A KR20150114980 A KR 20150114980A KR 20170023417 A KR20170023417 A KR 20170023417A
Authority
KR
South Korea
Prior art keywords
carnosine
zinc
alcohol
zinc complex
alkali metal
Prior art date
Application number
KR1020150114980A
Other languages
Korean (ko)
Other versions
KR101788268B1 (en
Inventor
육진수
이용섭
정재욱
박정화
김선미
이종수
강병규
Original Assignee
주식회사 엔지켐생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엔지켐생명과학 filed Critical 주식회사 엔지켐생명과학
Priority to KR1020150114980A priority Critical patent/KR101788268B1/en
Publication of KR20170023417A publication Critical patent/KR20170023417A/en
Application granted granted Critical
Publication of KR101788268B1 publication Critical patent/KR101788268B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic System
    • C07F3/003Compounds containing elements of Groups 2 or 12 of the Periodic System without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic System
    • C07F3/06Zinc compounds

Abstract

A method for easily synthesizing a crystalline L-carnosine zinc complex useful as an anti-ulcer therapeutic agent in a high purity and a high yield without a separate purification process. The method for producing the L-carnosine zinc complex comprises: suspending L-carnosine and zinc salt in an alcohol or a hydrated alcohol; Dissolving an alkali metal compound in an alcohol or a hydrated alcohol to prepare an alkali metal compound solution; Adding a solution of the alkali metal compound to the suspension of L-carnosine and zinc salt to precipitate an L-carnosine zinc complex; Adding purified water to the reaction solution containing the L-carnosine zinc complex; And filtering the L-carnosine zinc complex crystals.

Description

[0001] The present invention relates to a method for producing L-carnosine zinc complexes,

The present invention relates to a process for preparing L-carnosine zinc complexes, and more particularly, to a process for producing L-carnosine zinc complexes which can be conveniently synthesized in high purity and high yield without further purification, - < / RTI > carnosine zinc complexes.

The L-carnosine zinc complex represented by the following formula (1) is widely used as an anti-ulcer therapeutic agent such as gastric ulcer, and Korean Patent No. 10-0128514 discloses a production method thereof.

Figure pat00001

According to this document, when a solution obtained by dissolving sodium hydroxide in alcohol, adding L-carnosine to form a homogeneous solution and then dissolving zinc acetate dihydrate in methanol is added dropwise to the homogeneous solution of L-carnosine, crystalline L -Carnosine zinc complexes can be prepared. However, the L-carnosine zinc complex obtained by the above method has a disadvantage in that it is difficult to remove sodium acetate as a by-product, since crystals are fine and have poor filtration properties and are difficult to wash. Japanese Patent No. 04880332 discloses a method of dissolving L-caronosine and an alkali metal compound in an alcohol or a hydrated alcohol and then adding the zinc salt to a zinc salt solution at 40 to 80 캜 in which an anhydrous or hydrated alcohol is dissolved, L-carnosine < / RTI > complexes. However, in the above method, it is troublesome to dissolve L-carnosine in an alkali solution, and an L-carnosine zinc complex containing about 10% by-product sodium acetate is obtained. Therefore, as disclosed in Japanese Patent No. 04936737, there is a disadvantage that a separate purification (reprocessing) process using purified water is necessary.

It is an object of the present invention to provide a process for producing L-carnosine zinc complex which can produce L-carnosine zinc complex in high purity, high yield and large quantity. Another object of the present invention is to provide a method for producing L-carnosine zinc complex which can easily obtain an L-carnosine zinc complex without a separate purification process.

In order to accomplish the above object, the present invention provides a method for preparing L-carnosine, comprising: suspending L-carnosine and zinc salt in an alcohol or a hydrated alcohol; Dissolving an alkali metal compound in an alcohol or a hydrated alcohol to prepare an alkali metal compound solution; Adding a solution of the alkali metal compound to the suspension of L-carnosine and zinc salt to precipitate an L-carnosine zinc complex; Adding purified water to the reaction solution containing the L-carnosine zinc complex; And filtering the L-carnosine zinc complex crystals. The present invention also provides a method for producing L-carnosine zinc complex. Preferably, the amount of the purified water used is 2 to 30 times (ml / g, volume / weight ratio) of L-carnosine, and the purified water dissolves and removes impurities contained in the L-carnosine complex complex lattice It plays a role.

According to the present invention, it is possible to produce L-carnosine zinc complexes in high purity, high yield, and in a large amount without performing a separate purification process.

Hereinafter, the present invention will be described in detail.

According to the present invention, in order to prepare an L-carnosine zinc complex, L-carnosine and a zinc salt represented by the following formula 2 are suspended in an alcohol or a hydrated alcohol.

Figure pat00002

Examples of the zinc salt include inorganic salts such as zinc chloride, zinc halide such as zinc chloride and zinc sulfate, zinc sulfate, zinc nitrate and zinc perchlorate, and organic salts such as zinc acetate anhydrous, zinc acetate dihydrate and acetylacetone zinc , Preferably anhydrous zinc acetate, zinc acetate dihydrate, or zinc halide can be used. The amount of the zinc salt to be used is preferably 0.8 to 1.2 equivalents, preferably 0.9 to 1.1 equivalents, such as 1 equivalent, based on L-carnosine. If the amount of the zinc salt to be used is too small, there is a problem that the zinc content is lowered, and if it is too much, zinc hydroxide as an insoluble matter is generated and remains in the L-carnosine zinc complex. As the solvent for suspending the L-carnosine and the zinc salt, an anhydrous alcohol solvent such as methanol, ethanol, isopropanol, or a mixture thereof may be used or may be used in an amount of 50% by weight or less, preferably 30% by weight or less, For example, a mixed solvent of water and alcohol consisting of 1 to 20% by weight of water and the remaining alcohol may be used. The amount of the solvent to be used may be 1 to 30 times (ml / g, volume / weight ratio), preferably 2 to 15 times, more preferably 5 to 10 times, to L-carnosine.

Next, an alkali metal compound solution is prepared by dissolving the alkali metal compound in an alcohol or a hydrated alcohol. As the alkali metal compound, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium alcoholate, potassium alcohol and the like can be used, and sodium hydroxide, potassium hydroxide, sodium alcoholate or potassium alcoholate can be preferably used . As the solvent for dissolving the alkali metal compound, an anhydrous alcohol solvent such as methanol, ethanol, isopropanol or a mixture thereof may be used, or 50 wt% or less, preferably 30 wt% or less, for example, 1 To 20% by weight of water and the remaining alcohol may be used. The amount of the solvent to be used may be 2 to 30 times (ml / g, volume / weight ratio), preferably 3 to 20 times, more preferably 5 to 10 times, based on the alkali metal compound.

Next, the alkali metal compound solution is added to a suspension of the L-carnosine and the zinc salt to precipitate the L-carnosine zinc complex represented by the formula (1). The mixing ratio of the L-carnosine and zinc salt suspension and the alkali metal compound solution may be such that the alkali metal compound is 0.8 to 1.5 equivalents, preferably 0.9 to 1.2 equivalents, relative to the L-carnosine. If the amount of the alkali metal compound used is too small, there is a problem that the content of zinc is lowered, and if it is too much, there is a problem that impurities are generated. The reaction between the L-carnosine and the alkali metal compound is a protecting group forming reaction. The reaction temperature is usually from room temperature to the boiling point of the solvent to be used, for example, from 20 to 80 ° C, preferably from 40 to 70 ° C, 2 to 5 hours.

When the L-carnosine zinc complex is formed by the above reaction, purified water is added to the reaction solution in order to dissolve and remove impurities such as sodium acetate, which is a by-product contained in the L-carnosine complex complex lattice. The amount of the purified water used is 2 to 30 times (ml / g, volume / weight ratio), preferably 5 to 20 times, of L-carnosine. The crystalline L-carnosine complex can then be obtained by filtering, washing and drying the L-carnosine zinc complex crystals by conventional methods such as filtration and centrifugation.

According to the present invention, since the crystallinity of the L-carnosine zinc complex is good and the generation and the residue of the by-product sodium acetate can be minimized, the lowering of the content of the target compound and the poor filtration problem can be solved, There is no need to perform a separate process such as a slurry treatment for removing the slurry. Also, through the simple process of adding purified water after the reaction, it is possible to stably mass-produce L-carnosine zinc complex with high purity and high yield.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[Comparative Example 1] Production of L-Carnosine Zinc Complex

A 50,000 ml reactor was charged with 12.7 liters of methanol and 1.61 kg of zinc acetate dihydrate, and the mixture was heated to 50 캜 for dissolution. On the other hand, 17.7 liters of methanol and 587 g of sodium hydroxide were added to a 20,000 ml reactor and dissolved by stirring. The solution was cooled to 5 占 폚 and 1.66 Kg of L-carnosine was dissolved therein. This L-carnosine methanol solution was added dropwise to a methanol solution of zinc acetate dihydrate at 50 占 폚 over 1 hour. During the dropwise addition, the reaction temperature was adjusted to the range of 45 to 55 ° C, stirred at the same temperature for 2 hours and filtered to obtain 10.5 Kg of white powdery crystals. The white powder phase crystal was analyzed using NMR to find that the content of sodium acetate was 9.9% by weight.

[Comparative Example 2] Preparation of L-carnosine zinc complex

In a 10,000 ml reactor, 5,020 ml of methanol and 335 g of zinc acetate dihydrate were added and dissolved. On the other hand, in a 10,000 ml reactor, 3,800 ml of methanol and 122 g of sodium hydroxide were added and dissolved by stirring. The solution was cooled to 5 캜, and 345 g of L-carnosine was added thereto and dissolved. A methanol solution of zinc acetate dihydrate was added dropwise to the L-carnosine methanol solution for 30 minutes. The mixture was aged for 2 hours and then filtered to obtain 2050 g of a white powdery crystal. NMR analysis of the white powdery crystal revealed that the content of sodium acetate was 22.59% by weight.

[Example 1] Preparation of L-carnosine zinc complex

100 ml of methanol, 9.71 g of zinc acetate dihydrate and 10 g of L-carnosine were suspended in a 500-ml three-necked flask, and the suspension was gradually heated to maintain the temperature at 60 占 폚. 3.52 g of sodium hydroxide was completely dissolved in 70 ml of methanol to prepare a sodium hydroxide solution, which was then slowly added to the suspension. The reaction solution was stirred at 50 to 60 캜 for 1 hour, then cooled to 30 캜, and 80 ml of purified water was gradually added dropwise for 30 minutes. After the addition of purified water, the mixture was stirred at the same temperature for 1 hour, filtered under reduced pressure, washed sequentially with 80 ml of purified water and 80 ml of methanol, and dried to obtain 12.8 g of a white powdery crystal. NMR analysis of the white powdery crystal revealed that the content of sodium acetate was 0.5% by weight.

[Example 2] Preparation of L-carnosine zinc complex

100 ml of ethanol, 9.71 g of zinc acetate dihydrate and 10 g of L-carnosine were suspended in a 500-ml three-necked flask, and the suspension was gradually heated to maintain the temperature at 60 占 폚. 3.52 g of sodium hydroxide was completely dissolved in 70 ml of ethanol to prepare a sodium hydroxide solution, which was then slowly added to the suspension. The reaction solution was stirred at 50 to 60 캜 for 1 hour, then cooled to 30 캜, and 80 ml of purified water was gradually added dropwise for 30 minutes. After the addition of the purified water, the mixture was stirred at the same temperature for 1 hour and then filtered under reduced pressure. The filtrate was washed with 80 ml of purified water and 80 ml of ethanol successively and dried to obtain 12.8 g of a white powdery crystal. NMR analysis of the white powdery crystal revealed that the content of sodium acetate was 0.9% by weight.

Claims (4)

Suspending L-carnosine and a zinc salt in an alcohol or a functional alcohol;
Dissolving an alkali metal compound in an alcohol or a hydrated alcohol to prepare an alkali metal compound solution;
Adding a solution of the alkali metal compound to the suspension of L-carnosine and zinc salt to precipitate an L-carnosine zinc complex;
Adding purified water to the reaction solution containing the L-carnosine zinc complex; And
And filtering the L-carnosine zinc complex crystals.
The method of claim 1, wherein the zinc salt is selected from the group consisting of zinc acetate anhydrous, zinc acetate dihydrate and zinc halide. The method of claim 1, wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof, and the functional alcohol is a mixture of water and alcohol consisting of 50% by weight or less of water and the remaining alcohol Lt; RTI ID = 0.0 > L-carnosine < / RTI > The method of claim 1, wherein the purified water is used in an amount of 2 to 30 times (ml / g, volume / weight ratio) of L-carnosine, and the purified water dissolves impurities contained in the L- ≪ / RTI > wherein the L-carnosine zinc complex is prepared by reacting a compound of formula <
KR1020150114980A 2015-08-14 2015-08-14 Methods for producing L-carnosine zinc complex KR101788268B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150114980A KR101788268B1 (en) 2015-08-14 2015-08-14 Methods for producing L-carnosine zinc complex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150114980A KR101788268B1 (en) 2015-08-14 2015-08-14 Methods for producing L-carnosine zinc complex

Publications (2)

Publication Number Publication Date
KR20170023417A true KR20170023417A (en) 2017-03-06
KR101788268B1 KR101788268B1 (en) 2017-10-19

Family

ID=58399044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150114980A KR101788268B1 (en) 2015-08-14 2015-08-14 Methods for producing L-carnosine zinc complex

Country Status (1)

Country Link
KR (1) KR101788268B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200136167A (en) 2019-05-27 2020-12-07 주식회사 한서켐 New preparing method of Polaprezinc
CN114149452A (en) * 2021-12-08 2022-03-08 江苏诚信药业有限公司 Preparation method of L-carnosine zinc complex

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200002486A (en) 2018-06-29 2020-01-08 에스케이케미칼 주식회사 Wet granulation composition, tablet comprising same, and method for preparing the tablet
KR20200002409A (en) 2018-06-29 2020-01-08 에스케이케미칼 주식회사 Wet granulation composition comprising polaprezinc and method for preparing tablet using the same
KR20200137878A (en) 2019-05-31 2020-12-09 에스케이케미칼 주식회사 Dry granulation composition, tablet using the same and preparation method thereof
KR20200013018A (en) 2020-01-28 2020-02-05 에스케이케미칼 주식회사 Wet granulation composition comprising polaprezinc and method for preparing tablet using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4936737B2 (en) * 2006-01-31 2012-05-23 株式会社トクヤマ Method for producing crystalline L-carnosine zinc complex

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200136167A (en) 2019-05-27 2020-12-07 주식회사 한서켐 New preparing method of Polaprezinc
CN114149452A (en) * 2021-12-08 2022-03-08 江苏诚信药业有限公司 Preparation method of L-carnosine zinc complex

Also Published As

Publication number Publication date
KR101788268B1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
KR101788268B1 (en) Methods for producing L-carnosine zinc complex
AU2007298855B2 (en) Process for preparing N-alkyl naltrexone halides
KR100970434B1 (en) Method for purification of adefovir dipivoxil
KR101653064B1 (en) A Method for Gadobutrol
CN112654602A (en) Crystalline 2-fluoro-3-nitrotoluene and process for its preparation
JP2010513546A5 (en)
TW201912656A (en) Method for preparing sugammadex sodium and crystalline form thereof
KR20190088793A (en) Manufacturing method of calcobutrol
JP4880332B2 (en) Method for producing crystalline L-carnosine zinc complex
JP4079991B2 (en) Method for producing cesium salt from cesium aluminum alum
CA3050777C (en) Process for preparing fluorescein quinoid form
KR20190025131A (en) Gadobutrol intermediate and method for preparing gadobutrol using the same
JP3884063B2 (en) Cefcapene pivoxil methanesulfonate
KR100351743B1 (en) Process for preparation of the n,n-dicyclohexyl-2-benzothiazole sulfenamide
JPH08176150A (en) Production of 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole or its salt
CN100543027C (en) Preparation is used for the method for the intermediate of synthetic cynnematin
CN106008323A (en) Preparation method of pimavanserin hemitartrate crystal form C
KR101251741B1 (en) An improved process for preparing candesartan cilexetil
JP2016222632A (en) Tris(carboxyanthracenylphenyl)benzene, and crystalline network complex and gas storage material using the same
JP2021504458A (en) Method for producing salicylamide acetate
JPH03271267A (en) Production of bis(3,5-dibromo-4-(dibromopropoxy)phenyl) sulfone
KR20200143805A (en) Preparing method of crystalline polaprezinc using aqueous solution
CN116606244A (en) Synthesis method of 6-bromo-5-methoxypyridine-3-amine
JP5754842B2 (en) Method for producing p-iodophenol
JP2004307402A (en) Method for producing 2-carboxyethyl dimethylsulfonium sulfate

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)